BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Liquid Ready to Use Cystatin C Assay from Randox Provides a More Sensitive Marker of GFR Compared to Creatinine


12/20/2011 9:52:38 AM

Crumlin, UK, December 20, 2011 / B3C newswire / - As the prevalence of chronic kidney disease continues to increase dramatically so does the burden on healthcare resources worldwide. The early detection of kidney disease is crucial in order to reduce healthcare costs, avoid disease progression and the need for dialysis or transplantation. Traditionally creatinine was the most widely used marker of GFR and kidney function however several recent studies have documented Cystatin C as a far superior and sensitive marker. Cystatin C is produced at a constant rate throughout the body and is removed and broken down by the kidneys, levels will therefore remain steady if the kidneys are working efficiently and the GFR is normal.

Unlike Creatinine, Cystatin C is virtually unaffected by non renal factors including muscle mass, weight, height, age, gender, diet and drugs. This makes it particularly useful in cases where creatinine measurement is not appropriate e.g. in individuals who are obese, malnourished or who have liver disease. Cystatin C is also sensitive to changes in the ‘creatinine blind’ range enabling detection of early reductions in GFR and subsequent early treatment of kidney disease. In addition to this Cystatin C shows several other advantages over creatinine; the ability of Cystatin C to detect even small changes in GFR makes it the ideal marker for dosing medication eliminated by the kidneys. Cystatin C is also the preferred marker for estimating GFR in infants, the elderly, diabetics and those with reduced muscle mass.

The Randox Cystatin C assay is based on an immunoturbidimetric method and is suitable for use on a wide range of chemistry analysers. All reagents are supplied liquid ready to use for added convenience, furthermore reagents are stable for 28 days at +10oC onboard the analyser minimising the possibility of reagent waste. The assay has a wide measuring range of 0.4 to 10 mg/l allowing both normal and abnormal values to be measured accurately and reliably without the need for additional dilutions. Further benefits include excellent precision (CVs under 5%) and limited interference from bilirubin, haemoglobin, triglycerides and intralipids. A full range of supporting quality controls and calibrators are also available.

Although less research has been carried out, Cystatin C is believed to have applications in cardiology, oncology and clinical pharmacology.

About Randox

Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.



Read at BioSpace.com

Randox
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->